Foundation Life sciences is a Disabled American Veteran-owned biotechnology and biomanufacturing company, involved in both basic and clinical research and development of stem cells and other biologic products for human and veterinary markets, as well as for the new drug discovery/investigational new drug/clinical trials market. Our research includes the use of genomics and epigenetics to revolutionize regenerative treatments. We provide high-paying jobs in our community with on-the-job bio-education while strengthening the United States supply chain. We strive to help people live longer and healthier lives through advances in medicine.

Mission Statement:

To meet the need of clinicians and researchers for quality biologic products and to further regenerative research to help solve some of the greatest challenges facing humankind.

Product/Service:

We will soon have the capacity to supply a reliable volume of high-quality Wharton’s Jelly derived stem cells and extracellular vesicles for the international community. Our research focuses on identifying which patients will benefit from specific biologic treatments and providing personalized regenerative protocols for the treatment of difficult to treat diseases.

Market Size:

There is a growing international need. The global stem cell market is expected to grow from $10.2 billion in 2021 to $20.87 billion in 2025.

Sales/Marketing Strategy:

We will have representation at medical and government conferences. Our sales team will focus on reputable researchers and clinicians worldwide.

Target Market:

International medical clinics and researchers including academia, government, and private sector.

Financial Information:

Foundation Life Sciences is currently in a seed stage funding round.

Business/Revenue Model:

Domestic and international biologics sales, as well as research and joint ventures focused on intellectual property development and application.

Competitive Advantage:

Our team is composed of experienced experts in regenerative medicine and biotechnology. With our planned capacity, we hope to provide high quality products at competitive rates. We also hope to become the leader in addressing the patient-specific needs of researchers with epigenetically driven therapies.